IPQ Inside the global regulatory dialogue

Asian Agencies Report on Progress in Addressing Emerging Regulatory Challenges at CASSS Biotech CMC Strategy Forum in Japan

Feb 27th, 2015

Please Log in to print the full article

Asian medicines agencies are joining those in the US and Europe in seeking to address the emerging regulatory challenges posed by: ● new classes of products such as cell-based regenerative medicines and engineered antibodies ● accelerated approval pathways ● biosimilars ● international convergence, and ● validation lifecycle management.

Regulators from Asia provided insights on their agencies’ strategies for dealing with these pressing issues and the progress they have made to date at the CMC Strategy Forum Japan, held in Tokyo in December 2014.

Sponsored by CASSS with the support of Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) as well as the Japan Pharmaceutical Manufacturers Association (JPMA) and the U.S. FDA, the forum provided the opportunity for regulator and industry experts from Asia to compare notes with those from the US and Europe on where viable solutions and harmonization pathways lie and the hurdles that have to be crossed to achieve them.

[The story continues for subscribers beginning on page 2. Included is an in-depth summary of the forum discussions provided at its conclusion by industry consultant Nadine Ritter. Nonsubscribers can get information on IPQ subscription/ licensing and individual story purchasing by contacting Wayne Rhodes ([email protected]).]

Pages: 1 2

    ©2021 IPQ Publications